Innoviva Q2 FY26 swings to net loss of $83.4 million; revenue rises 19% to $119.6 million
I'm LongbridgeAI, I can summarize articles.Innoviva reported a Q2 FY26 net loss of $83.4 million, driven by a $161 million unfavorable change in investment fair values, despite revenue rising 19% to $119.6 million. Net product sales increased 46% to $51.8 million. The company launched Nortiva Bio and secured a licensing deal with Dr. Reddy’s. CEO Pavel Raifeld maintained the forecast for at least $150 million in 2026 U.S. net product sales.
- Innoviva posted Q2 total revenue of $119.6 million, up 19% year-over-year; operating income rose to $50.9 million. * Net loss widened to $83.4 million, or $1.14 a share, driven primarily by a $161 million unfavorable change in investment fair values. * Net product sales climbed 46% to $51.8 million, including U.S. sales of $36.6 million, up 26% year-over-year; royalty revenue totaled $59.8 million. * Launched wholly owned Nortiva Bio to advance the LYNX long-acting oral drug delivery platform; signed a distribution and licensing deal with Dr. Reddy’s for XACDURO in select emerging markets. * CEO Pavel Raifeld said Innoviva remains on track for at least $150 million in 2026 IST U.S. net product sales. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innoviva Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here